((自动化翻译由路透提供，请见免责声明 ))
1月6日 - ** 医疗保健产品分销商 Henry Schein 股价上涨 ~4% 至 71.94 美元
** BofA Securities将该公司股票评级从 "跑输大市 "上调至 "买入"；将目标股价从69美元上调至84美元
** 券商称，HSIC 是 "最佳的牙科资产"，有能力以健康的速度实现盈利增长，与 COVID-19 之前的表现类似。
** 由于接触到高增长的牙科服务机构(DSO) 客户和自有品牌产品，公司处于从分销商和制造商获得份额的有利位置 - BofA Securities
** HSIC拥有 "牙科行业最佳投资组合"，对DSO客户的风险敞口高于市场水平，为公司的长期成功奠定了基础--券商
** 15 家券商中有 6 家将该股评级为 "买入 "或更高，7 家为 "持有"，2 家为 "卖出"；PT 中位数为 75 美元--数据由 LSEG 编制
** 2024 年恒生指数下跌 8.6
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.